News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tianjin CanSino Biotech Raises $10 Million From Lilly Asia Ventures


9/17/2013 8:44:47 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

September 17, 2013 -- Tianjin CanSino Biotechnology has received a $10 million strategic investment from Lilly Asia Ventures, a venture capital arm of Lilly. CanSino specializes in the R&D and manufacture of human vaccines. CanSino will use the capital for R&D, clinical research and early stage commercialization of core combined DPT (diphtheria, pertussis and tetanus) vaccines and several other innovative vaccines. CanSino seeks to develop and market leading-edge, high quality vaccines for China and other emerging markets at an affordable cost. More details....

Stock Symbol: (NYSE: LLY)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES